Published in Psychopharmacol Bull on January 01, 2011
Thoughts on selected movement disorder terminology and a plea for clarity. Tremor Other Hyperkinet Mov (N Y) (2013) 0.76
An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Neuropsychiatr Dis Treat (2013) 0.75
Effects of needs-assessment-based psycho-education of schizophrenic patients' families on the severity of symptoms and relapse rate of patients. Iran J Nurs Midwifery Res (2014) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care (1996) 70.87
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
A new depression scale designed to be sensitive to change. Br J Psychiatry (1979) 36.40
The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry (1976) 15.48
A children's global assessment scale (CGAS). Arch Gen Psychiatry (1983) 12.78
A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl (1970) 10.05
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol (1998) 9.33
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
A rating scale for drug-induced akathisia. Br J Psychiatry (1989) 7.30
UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull (2001) 5.89
The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull (1984) 5.69
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl (1987) 4.49
Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res (2009) 3.68
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res (2004) 3.57
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Assessment of insight in psychosis. Am J Psychiatry (1993) 3.48
Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand (2000) 3.14
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl (2003) 2.63
Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res (1992) 2.49
Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol (2004) 2.43
Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res (2005) 1.66
Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res (2001) 1.56
Subjective response to neuroleptics in schizophrenia. Schizophr Bull (1993) 1.54
The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res (2003) 1.51
A review of instruments for measuring functional recovery in those diagnosed with psychosis. Schizophr Bull (2008) 1.33
Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull (2001) 1.27
Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr Res (2008) 1.23
Measuring outcome priorities and preferences in people with schizophrenia. Br J Psychiatry (2005) 1.03
A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 1.01
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res (2002) 1.00
Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol (2009) 1.00
Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl (2007) 1.00
Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res (2005) 0.88
Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol (2003) 0.87
Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry (2009) 0.85
Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr Res (2008) 0.85
"The trouble with QALYs...". Epidemiol Psichiatr Soc (2008) 0.84
Quality of life in patients who have remitted from their first episode of psychosis. Schizophr Res (2010) 0.81
Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophr Res (2009) 0.81
Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol (2010) 0.80
Treatment target in schizophrenia: a critical review and a clinical suggestion. Psychopharmacol Bull (2008) 0.80
Overview of the findings from the European SOHO study. Expert Rev Neurother (2008) 0.80
Subjective life satisfaction and objective living conditions of patients with schizophrenia in Nigeria. Psychiatr Serv (2010) 0.79
Magnitude of rater differences in assessment scales for schizophrenia. J Clin Psychopharmacol (2010) 0.78
Hopelessness as a predictor of work functioning among patients with schizophrenia. Psychiatr Serv (2004) 0.78